Oxford Pharmascience Group (OXP)

 

OXP Share PerformanceMore

52 week high7.6220 25/05/16
52 week low1.5000 30/12/16
52 week change -6.0850 (-78.52%)
4 week volume15,833,174 29/04/17

Media for (OXP)

Presenter: Marcelo Bravo
25/01/2017
Presenter: Marcelo Bravo
13/09/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Update regarding OXPzeroTM Ibuprofen Programmes

RNS Number: 5321E Oxford Pharmascience Group PLC 09 May 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Update regarding OXPzeroTM Ibuprofen Programmes Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, pr...

Miners drag on FTSE as commodity prices fall

Weaker commodity prices hit miners with Anglo American (AAL), Antofagasta (ANTO) and BHP Billiton (BLT) falling b...

Second Price Monitoring Extn

RNS Number: 1522B Oxford Pharmascience Group PLC 31 March 2017 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-d...

FTSE falls on miners, financials as Old Mutual suffers

London shares were a little lower in early deals with heavyweight miners providing decisive ballast, but Old Mutual took t...

Price Monitoring Extension

RNS Number: 1516B Oxford Pharmascience Group PLC 31 March 2017 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before ...

Oxford Pharmascience disappointed with FDA feedback

Oxford Pharmascience Group said the US FDA has not agreed with the proposed phase III study design for the OXPzero Ib...

FDA Feedback on OXPzeroT Ibuprofen Rx Programme

RNS Number: 1026B Oxford Pharmascience Group PLC 31 March 2017 31 March 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") FDA Pre-IND Feedback on OXPzero Ibuprofen Rx programme Oxford Pharmascience Group plc (AIM: OXP), the speciality pharmaceutical company that redevelops medicines to make them better, s...

Oxford Pharmascience narrows FY pretax loss

Oxford Pharmascience has roughly halved its FY pretax loss to 1.9m, from a loss of 3.9m a year earlier. Revenues totalled 7...

Fundamental DataMore

EPS-0.11
Dividend yield0 %

Latest discussion posts More

  • Re: At least 18 months

    That seems logical, I will hold on in the HOPE it passes 2p and take a small profit, if not, leave for 2 or 3 years and most probably have this same conversation again.
    3-Apr-2017
    Hyperproject
  • Re: At least 18 months

    I've bailed after a big hit! The way I read it, they have no product. If they want to release it as planned then they need more trials which could cost millions and also, ...
    2-Apr-2017
    high blood pressure1
  • At least 18 months

    I have committed today at 1.7p, my first investment ever in anything outside the FT250. From my understanding of this sector, I don't expect much movement either up or down for ...
    31-Mar-2017
    Hyperproject

Users' HoldingsMore

Users who hold Oxford Pharmascience Group also hold..
SIRIUS MINERALS16%
LLOYDS GRP.16%
ID:ISIN:VGG9828A119413%
OXFORD BIOMED.13%
88 ENERGY13%

Codes & Symbols

ISINGB00B3LXPB43
SymbolsOXP, LSE:OXP, OXP.L, OXP:LN, LON:OXP, XLON:OXP